Trial Profile

Small food effect study of CLN-081

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 22 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zipalertinib (Primary)
Indications Non-small cell lung cancer
Focus Pharmacokinetics

Most Recent Events

16 Apr 2024 According to Cullinan Therapeutics media release, Cullinan Oncology has changed its name to Cullinan Therapeutics.
04 Apr 2022 New trial record
28 Mar 2022 According to an Cullinan Oncology media release, The FDA has endorsed Cullinan's plan to conduct a small food effect study (n=20) that is designed to evaluate the potential impact of food on exposure and other pharmacokinetic (PK) parameters at 150mg

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com